Redhill Biopharma Stock News

NEW YORK, Nov. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CARA, RDHL, BYSI, ATIP, and CODX. To see how InvestorsObserver''s proprietary scoring system rates these stocks, view the InvestorsObserver''s PriceWatch Alert by selecting the corresponding link….

RedHill Biopharma Ltd (NASDAQ:RDHL) has reported its financial results and operational highlights for the third quarter ended September 30, 2021, showing a second consecutive quarter of record net rev

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Cumberland Gets FDA Approval For IV-Delivered Ibuprofen For Use In Pre-Operative Administration Cumber

  RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results   RedHill Accelerates its Two Advanced COVID-19 Pill Clinical Programs in Light of their Potential Against Omicron   Acting independently of spike protein mutation, opaganib and RHB-107's unique host-targeted mechanisms of action hold potential versus Omicron and other variants -- Phase 2/3 study sub-population analysis demonstrated a 62% reduction in mortali...

RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial ResultsRedHill Accelerates its Two Advanced COVID-19 Pill Clinical Programs in Light of their Potential Against Omi

RedHill Accelerates its Two Advanced COVID-19 Pill Clinical Programs in Light of their Potential Against Omicron Acting independently of spike protein mutation, opaganib and RHB-107''s unique host-…

RedHill Accelerates its Two Advanced COVID-19 Pill Clinical Programs in Light of their Potential Against Omicron Acting independently of spike protein mutation, opaganib and RHB-107''s unique host-targeted mechanisms of action hold potential versus Omicron and other variants -- Phase 2/3

RedHill Biopharma Ltd. (NASDAQ:RDHL) has a beta value of 1.73 and has seen 0.69 million shares traded in the recent trading session. The company, currently valued at $192.18M, closed the recent trade at $2.74 per share which meant it lost -$0.26 on the day or -8.67% during that session. The RDHL stock price is -320.44% RedHill Biopharma Ltd. (RDHL) Is Becoming Less Appealing To Investors After A -8.67% Fall Read More »

Redhill Biopharma - ADR (RDHL) shares closed this week 26.5% lower than it did at the end of last week. The stock is currently down 64.7% year-to-date, down 66.7% over the past 12 months, and down 75.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 0.1%. Trading Activity Shares traded as high as $4.18 and as low as $2.57 this week.Trading volume this week was 33.3% lower than the 10-day average and 37.2% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 3105.4% The company's stock price performance over the past 12 months lags the peer average by 4298.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Brokerages forecast that RedHill Biopharma Ltd. (NASDAQ:RDHL) will post ($0.48) earnings per share for the current quarter, according to Zacks. Two analysts have made estimates for RedHill Biopharmas earnings, with the lowest EPS estimate coming in at ($0.50) and the highest estimate coming in at ($0.46). RedHill Biopharma reported earnings of ($0.50) per share in []

The trading price of RedHill Biopharma Ltd. (NASDAQ:RDHL) closed lower on Monday, November 22, closing at $2.73, -3.53% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Shares of RedHill Biopharma Ltd. (NASDAQ:RDHL) have earned an average rating of Buy from the six research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12-month price target among brokers that []

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talk will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify.

RedHill Biopharma Ltd. (NASDAQ:RDHL) has been assigned a consensus recommendation of Buy from the six ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that []